Background: The present study was conducted to examine the survival of patients with triple negative breast cancer subtype undergoing current chemotherapy and along with implanting weight management, physical activity and diet in breast cancer survivorship.
Patients and methods: The present study was conducted on 110 patients admitted to the oncology clinics of Talaghani Hospital of Kermanshah University of Medical science between October 2009 and July 2018. Patients started 5 chemotherapy cycles, including docetaxel, epirubicin and cyclophosphamide once every 21 days, and then two cycles of epirubicin and cyclophosphamide, ending with fluorouracil. Also recommend patients for physical exercise, diet and lifestyle change.
Results: The median and mean follow-up was 52.3 and 45.6 months respectively. 8 patients were metastatic and 103 were under adjuvant therapy, 13 of whom had relapses. Median relapse-free survival and mean overall survival were 44.4 months and 49.2 months, in respective order of the total of 110 patients, 20 died and 90 still live.
Conclusion: Along with recommendations for physical exercise, diet and lifestyle change, combination chemotherapy increases hopes for a better response to treatment and a reduction in the rate of relapse during the first three years.
Published Date: 2022-03-18; Received Date: 2022-02-18
